Abstract:e18733 Background: Although PD-1/PD-L1 inhibitors have become the standard treatment for patients with advanced non-small cell lung cancer (NSCLC), data from clinical trials are difficult to be verified in the real world. This study aims to compare the differences in population characteristics, treatment modes and clinical outcomes of advanced NSCLC patients received PD-1/PD-L1 inhibitors between the real-world (RWS) and the clinical study (RCT). Methods: This study enrolled 305 advanced NSCLC patients who received at least one PD-1/PD-L1 inhibitor treatment selected in the Affiliated Cancer Hospital of Zhengzhou University/Henan Cancer Hospital Information System and the Zero Krypton database during January 2016 to September 2019. The patients were divided into RWS group and RCT group. The PD-1/PD-L1 inhibitors included pembrolizumab, sintilizumab, nivolizumab, tislelizumab, carrelizumab, teriprizumab, durvalizumab and Atezolizumab. We performed paired analysis in clinical characteristics and treatment modes. Results: There were 155 cases in the RCT group and 150 cases in the RWS group. The RCT group consisted of higher proportion in male (79.4%) and squamous-carcinoma type (41.3%) than the RWS group, while more patients of brain metastasis (28%) and combination therapy (50.7%) in the RWS group. The ORRs were 42.4% and 20.6% respectively in the RCT and RWS groups receiving first-line treatment with PD-1/PD-L1 inhibitors, and the difference was statistically different. Moreover, the ORRs were 42.4% and 20.6% respectively in the RCT and RWS groups receiving PD-1/PD-L1 inhibitor as second-line treatment, without statistical difference. The progression-free survival (PFS) was 15.5 vs. 13.5 months in the RCT and RWS groups ( P= 0.91), and the median overall survival (OS) was 25.4 vs. 33.8 months respectively ( P= 0.24), with no statistical difference. After propensity match of baseline characteristics of the two groups of patients, it contained 108 patients in the RCT and RWS groups. The PFS was 13.3 vs. 13.3 months in the RCT and RWS groups ( P= 0.47), and the median OS was 21.1 vs. 23.2 months ( P= 0.58), with no statistical difference. Conclusions: Although more female, brain metastases and adenocarcinoma patients receiving PD-1/PD-L1 inhibitors in the real world, the clinical benefits were consistent with those in clinical trials. The results of propensity matching on the baseline characteristics of patients supported this conclusion.

Comparison of Clinical Characteristics and Prognoses of Patients with T1 Non-Small Cell Lung Cancer and Small Cell Lung Cancer in a Chinese Real-World Study.

A Real-World Observational Study To Explore Clinical Characteristics Of Chinese Patients With T1 Non-Small Cell Lung Cancer Complicated With Lymph Metastases.

Lymph node metastasis in Chinese patients with clinical T1 non-small cell lung cancer: A multicenter real-world observational study.

Real-world Surgical Treatment Patterns and Clinical Outcomes in Patients with Stages IA–IIIA Non-Small Cell Lung Cancer: a Retrospective Multicentric Observational Study Involving 11,958 Patients

Clinical Characteristics of Patients with Lymph Skip Metastases and Prognoses of Chinese Patients with Pn2 Non-Small Cell Lung Cancer.

Preoperative Lymph Node Assessment in Surgically Resected Pathologic T1 Lung Cancer Patients: Real World Clinical Practice in China.

Characterization of Never-Smoking and Its Association with Clinical Outcomes in Chinese Patients with Small-Cell Lung Cancer

Comparison of Surgeries Plus Perioperative and Postoperative Chemotherapies in Chinese Pn2 Patients with Non-Small Cell Lung Cancer: A Real-World Observational Study.

Risk Analyses of N2 Lymph-Node Metastases in Patients with T1 Non-Small Cell Lung Cancer: a Multi-Center Real-World Observational Study in China

Characterization of Distinct Types of KRAS Mutation and Its Impact on First-Line Platinum-Based Chemotherapy in Chinese Patients with Advanced Non-Small Cell Lung Cancer

Clinical Analysis of Sixty-Four Patients with T1an2m0 Stage Non-Small Cell Lung Cancer Who Had Undergone Resection

Analysis of the T descriptors and other prognosis factors in pathologic stage I non-small cell lung cancer in China.

Prognostic factor analysis of patients with small cell lung cancer: Real‐world data from 988 patients

[Study on the Prognosis of the T1a Non-Small Cell Lung Cancer].

Different treatment modalities on the prognosis of patients with stage I–IIIa small cell lung cancer: a population based study

The Prognostic Significance of the Histological Types in Patients With Nonsmall Cell Lung Cancer <= 2 cm

Clinical characteristics and prognostic factors of surgically resected combined small cell lung cancer: a retrospective study

Comparison of population characteristics, treatment modes, and clinical outcomes of patients with advanced non-small cell lung cancer in clinical trials and in the real world received PD-1/PD-L1 inhibitor.

T1aN0M0 and T1bN0M0 non-small cell lung cancer: a retrospective study of the prognosis.

Real-world Clinical Characteristics and Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) Patients in China.

Huge Heterogeneity Of Patient Characteristics, Treatment Patterns, Hospital Costs Exists In Non-Small Cell Lung Cancer Surgeries Among Different Centers Of China: A Study Of 5060 Patients Based On The Chinese National Nsclc Outcome Registry.